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Abstract
Demodicosis is one of the most common diseases of the skin. Despite the large number of scientific publications 
on this issue the question of the etiology and pathogenesis of this disease still remains unresolved and the development of 
more effective methods of treatment and prevention has not only medical but also social significance as patients preserv-
ing the working ability have actually long enough to be on outpatient and even inpatient treatment. In addition the long 
existence of the rash on the face that is the “business card” leads to the secondary sometimes severe neurotic disorders 
that results in reducing abilities, isolation, unwillingness to be in a team, family, etc.
We investigated the effect of complex therapy which had been conducted by means of antiparasitic, immuno-
modulatory, anti-inflammatory and desensitizing drugs in patients with demodicosis, as well as mandatory adjustment 
of changes in the hepato- panсreato-duodenal system. We examined 109 patients with demodicosis from 18 to 39 years 
old and 10 healthy individuals of the corresponding age and sex. It was established that the effectiveness of treatment of 
demodicosis based on the application of albendazole in the complex treatment along with immune-modulating therapy 
and hepatoprotection increased significantly. There has been a reliable rapid regression of clinical symptoms in most 
patients with demodicosis. 
Keywords: demodicosis, hepato-pankreato-duodenal zone (HPDZ), antiparasitic therapy, acaricidal prepara-
tions, delayed-type hypersensitivity (DTH) reactions.
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1. Introduction
Demodicosis – a skin disease which can be caused not only by the mite (demodex), but 
also by the presence of a number of factors: changes in the function of the sebaceous glands in the 
skin and reduced immunity. It is under these conditions when subcutaneous mite begins to mul-
tiply. It is very small, it is particles of mm long (it cannot be seen with your eyes) [1]. Demodex 
lives on the skin of most people without causing any changes. Demodex often begins multiplying 
during the puberty period when hormones influence the changes in the composition of sebum and 
necessary nutrient medium for mite reproduction appears. Multiplying demodex begins to cause 
inflammation in the skin [2].
Demodicosis is an associated disease in the occurrence of which disturbances in adap-
tive-protective properties of the body play an important role.
Specific chemotherapy is known to be the leading treatment for parasitic diseases. But very 
often the course of demodicosis is a constant chronic disease against the background of hepato- 
pankreato- duodenal system pathology which in turn leads to complications in its course. At dis-
turbances of the immune status of the host even active chemotherapy does not produce any effect 
or fast reinfection occurs [3]. Therefore a topical treatment alone does not usually produce clinical 
effect. Furthermore it is not an open secret that the antiparasitic therapy possesses a significant tox-
ic effect on the entire body [4]. Therefore its implementation should be duplicated with the means 
eliminating the harmful effects of chemotherapy. Side effects and complications of antiparasitic 
therapy also require the development of special schemes for specific pathogenetic therapy and che-
motherapy with the use of complex treatment to eliminate any negative effects.
Thus for the successful treatment of patients with demodicosis one should consider not only 
the form and stage of the disease but also changes in other organs and systems. Complex treatment 
should include along with antiparasitic therapy immunomodulatory, anti-inflammatory and desen-
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sitizing ones as well as compulsory correction of changes in the hepato-pankreato-duodenal sys-
tem, which in its turn will significantly increase the effectiveness of treatment of demodicosis [5].
In the development of the pathological process in demodicosis immunological and immuno-
pathological reactions occupy an important place [6]. Therefore parasitico-genic immunosuppression 
which produces inhibitory effect on metabolism, enzymatic activity and this hinders the absorption 
of antiparasitic chemotherapeutic drugs is of a great importance at structural and functional disorders 
of hepato-pankreato-duodenal zone (HPDZ). Toxic action of antiparasitic drugs, sensitizing effect 
of mite allergens, autoimmune action of host tissue necrosis products have a negative effect on the 
HPDZ organs due to cytopathogenic action of chemotherapy and parasites decomposition products. 
Apart from that it should be noted that the difficulties in the therapy of demodicoses which 
is far from being always successful even when using the most effective acaricides are related to the 
features of the composition of mite coatings. Demodex cuticle consists of three layers (external one is 
epiticule, the medium is exocuticule and the internal is endocuticle) and the structure is most devel-
oped in females [7]. A characteristic feature of the structure of the cuticle is that in the inner layers of 
exo- and endocuticles there are no poriferous canals connected with the external medium that is why 
it can only participate in the water and gas exchange. For this reason the passage of large molecules 
of exogenous substances in particular of contact acaricides through the demodex cuticle is difficult or 
even impossible. It is the fact which explains the difficulty in anti-parasitic therapy for demodicosis, 
the need for long treatment courses and choice of drugs with a minimal size of molecules [8]. 
Aims. To carry out a study of the clinical efficiency of new antiparasitic drugs and their 
application in combination with immunomodulatory therapy.
2. Materials and methods
We have examined 109 patients suffering from demodicosis from 18 to 39 years old (includ-
ing 49 men and 60 women) and 10 healthy individuals of the corresponding age and sex.
All the patients underwent common clinical and laboratory examination as well as immuno-
logical studies such as hormonal – we determined adaptive hormones rate (cortisol and insulin) in 
the blood, leukocyte intoxication index (LII), HPDZ organs were examined too [9].
According to the anamnesis, the duration of illness was as follows: up to 6 months in 
6 (6 %) patients, up to1 year in 19 (17 %) patients, up to 3 years in 28 (26 %) patients, up to 5 years 
in 33 (30 %) patients, up to 10 years in 15 (14 %) patients, and over 10 years in eight (7 %) patients.
We noticed mostly a chronic course of demodicosis issuing from the lack of effectiveness of 
conventional treatments.
In most patients the inflammation process was localized on the skin of their face, in some 
patients it also spread to the neck area, the chest, the back and auricles. It should be noted that only 
12 of the 109 patients complained of slight itching and burning in lesions areas; there were not any 
other subjective complaints. The clinical course in patients with demodicosis was characterized by 
a strong seasonality, with exacerbation in spring and summer.
In 98 (89.9 %) out of 109 patients with demodicosis we found comorbidities of HPDZ organs 
and in 86 (79 %) of them intestinal parasitoses (enterobiosis and giardiasis) were detected.
Depending on the severity of disease and its prescription, the patients with demodicosis 
were divided into three groups. The first group included 43 patients who took antiparasitic drug 
albendazole as a component of combined therapy. The second group consisted of 48 patients who 
took antiprotozoal drug ornidazole in the combined therapy and the rest 18 patients with demod-
icosis took albendazole and ornidazole in the combined therapy. We did not use acaricidal agents 
with contact action in our study.
3. Results 
We defined the following goals while treating demodicosis: to eliminate the infectious 
agent, to exclude any skin irritative effects, to restore the immunity, to normalize blood circulation, 
contributing to skin restoration
All the patients underwent combined treatment which included antiparasitic, immunomodu-
latory, anti-inflammatory and desensitizing therapies, as well as mandatory adjustment of changes 
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in the hepato-pankreato-duodenal system, which in its turn significantly increased the effective-
ness of treatment of demodicosis.
All the patients who received albendazole and ornidazole were quite tolerable to them. None 
of the patients had any adverse effects or changes in clinical and laboratory findings that could be 
related to the drug taking.
While treating demodicosis the patients took ornidazole parenterally within 10 days in a 
dose of 500 mg twice a day.
There were not any side effects. Contraindications: early pregnancy, lactation, patients with 
affected CNS. Efficiency: 98–99 %.
A drug called albendazole can be chosen for treatment of demodicosis (the first domestic 
anti- helminthic preparation of albendazole is Aldazole) and it is highly effective in mono and poly-
invasions, it has larvicide, ovicide and vermicide action (it affects mature parasites, their eggs and 
larvae. High therapeutic activity and broad spectrum of albendazole (aldazole) effect is provided 
through a dual mechanism of the action [10]:
– inhibition of tubulin protein synthesis which leads to a disruption of the cytoskeleton 
of the parasite;
– inhibition of fumarate hydratase (the main enzyme in the Krebs cycle of the parasite) 
resulting in the disruption of synthesis and glucose uptake. Both mechanisms of action cause the 
death of the parasite.
These drugs were administered in case of demodicosis in a dose of 400 mg twice a day for 
10 days after meals. 
Patients took 2 capsules of “Hepadif” 2–3 times a day regardless of the meal. The capsules 
should be usually taken in whole with water. If swallowing is difficult the contents of the capsule 
can be dissolved in 50 ml of juice or water. Clinical and laboratory examination of the patients 
taking Hepadif showed that their general condition improved much sooner [11]. Their clinical and 
laboratory findings got normalized including the parameters of cellular and humoral immunity.
In addition, we conducted a comprehensive symptomatic, immunomodulatory, desensitiz-
ing, detoxificating and general health-improving therapy. 
As to general health-improving drugs we preferred vitamins. The patients took:
1. Berocca plus – 1t/once a day/any time/for 30 days (vitamin B 1–12, C).
2. Aevit – 1t/twice a day/while eating/for 30 days (vitamin A – E).
3. Selenium active – 1t/once a day/while eating/for 30 days (vitamin).
4. Zincteral – 1t/3 times a day/after meals/for 30 days (vitamin zinc).
5. Omega 3-6-9 fatty acids – 1t/3 times a day/while eating/for 30 days.
The diet and the regimen are very important too. It is recommended to follow the principles 
of rational nutrition in order to resume proper metabolism [12]. The diet should contain enough 
protein, fat, carbohydrates, vitamins and minerals. But animal proteins should be mainly presented 
by dairy products, lean meats, fish and poultry meats, and the fats with vegetable oils and butterfat. 
It is recommended to eliminate completely high-melting animal fats (beef, goose, mutton fats and 
others) replacing them with vegetable oils and butterfat. 
Great importance is attached to carbohydrates as a source of constant energy. But we should 
only consume compound carbohydrates which are broken down gradually in the bowels and be-
come a source of constant energy (vegetables, grains). We should exclude completely easily digest-
ible carbohydrates (sweets and cakes). We also exclude spicy, fried, smoked and canned food – all 
these disturb the metabolism and irritate the skin. Alcohol and smoking are strictly prohibited [13]. 
A correct regimen is equally important. Demodicosis lives 24 days so you should keep your per-
sonal sterile for 30 days to avoid recurrent autoinfection [14]. Specifically:
– to change your bed linen every 3 days, to iron and to steam your pillow and its slip daily 
as well as other personal things; 
– to use disposable wipes if towels are not available; 
– to change towels after each washing. 
Patients with demodicosis are not recommended to stay in the sun for a long time or use 
artificial methods of tanning as well as to expose their skin to wind, rain, snow, dust and other 
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influences which might increase its irritation and to use various thermal procedures such as baths, 
saunas and so on [15]. 
To reduce the irritant effect of the nervous system on the skin the patients are prescribed de-
bilitants and those with sleep disorders are administered light hypnotic. For the same reason they un-
dergo such physiotherapeutic procedures as electrosleep [16]. Moderate physical exercise and walks 
in the open air under the slanting sun rays (in the morning and in the evening) are also recommended. 
In general, it should be noted that in the majority of patients with demodex after combined 
therapy despite the improvement in the general condition and relative, varying degrees of severity, 
regression of changes existed before treatment, takes place the full normalization of clinical and 
laboratory parameters characterizing the functional state of the liver indicating the resistance of 
these disorders.
Depending on the dynamics of both subjective and objective clinical symptoms and the re-
sults of repeated clinical and laboratory examination allowed to assess the nature and direction of 
development of the changes existed before treatment we adopted the following scale assessing the 
efficiency of complex treatment of patients with demodex [17]:
1) degree of effectiveness (complete recovery) was characterized by the disappearance of 
the subjective and objective clinical and laboratory signs of disease, the reverse development of 
changes observed before treatment;
2) degree ( improvement) was characterized by the disappearance of the subjective and objec-
tive evidence of a significant reduction characteristic of demodectic mange in the acute phase, with a 
distinct tendency to regression of clinical and laboratory violations observed before treatment;
3) degree (no change) was characterized by a decrease of subjective symptoms at the 
absence of significant changes indicating regression of clinical and laboratory abnormalities 
existed before treatment;
4) degree (deterioration) was determined in patients with small subjective improvement or 
no deterioration of objective indicators testifying about the rise of pathological changes in the liver.
Comparative evaluation of reverse development of clinical symptoms after 2–5 months after 
treatment showed (Fig. 1, 2) that the absence or reduction of complaints is not always accompanied 
with an improvement of objective clinical parameters.
The amelioration was characterized by positive dynamics in the general condition of the pa-
tient, a significant regression of clinical symptoms and a reduction of objective signs of the disease, 
improvement of hematological parameters while maintaining positive immunological tests.
A reliable rapid regression of clinical symptoms in most patients with demodicosis justifies 
the advisability of administering these drugs and points out the positive effects of their use.
After complex therapy there were observed different degrees of regression of changes exist-
ed treatment. The lack of clinical response on therapy may be due to the already established treat-
ment pathology HPDZ [18]. This is confirmed by the growth of pathological changes in clinical and 
laboratory parameters that caused an increase of demodicosis mange duration.
Fig. 1. The nature and frequency (%) of change of subjective clinical symptoms in demodicosis 
patients 2–5 months after the combined therapy: 1 – normalization; 2 – improving;  
3 – unchanged; 4 – deterioration
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Fig. 2. The nature and frequency (%) of changes in objective clinical symptoms in patients with 
demodex in 2–5 months after the complex therapy: 1 – normalization; 2 – improving; 
3 – unchanged; 4 – deterioration
4. Discussions
The variety and number of means of the specific combined therapy did not only suggest 
achieving parasitological effect. In order to find possible ways of accelerating the recovery of long 
flowing disturbances in the immunity patients were prescribed a hepatoprotector “Hepadif” along 
with anti-parasitic and conventional pathogenic treatment. This is a combined medication which 
pharmacological effects is the result of complex action of its components. It stimulates the me-
tabolism of fats – components of β-oxidative conversion of free fatty acids in the mitochondria 
of hepatocytes, biosynthesis processes, prevents necrosis of hepatocytes, normalizes processes of 
proliferation of hepatocytes, liver enzyme system and helps to restore normal liver function.
As demodicosis occurs at lower immunity we made its correction and recovery of correct 
metabolic processes and protective properties of the skin. The action of the immune system as 
response on aggression of Demodex mite remains largely unexplored (as in most of other parasitic 
diseases). We can assume that living activities of the immune system restrains the parasite repro-
duction and its presence in the body in small quantities which does not lead to the development 
of clinical disease. In case of increasing the number of agents (due to some reasons) the immune 
system begins to respond more actively starting the mechanisms of inflammatory reactions. 
Delayed-type hypersensitivity (DTH) reactions play a primary role in аntiparasitic immune pro-
cesses. At demodicosis for example it is proved that the expansion of demodectic nidus causes a severe 
infiltration of its external wall by eosinophils, neutrophils, histiocytes and by the cells of lymphocytic 
series. And phagocytes accumulated around the parasite affect it with the enzymes of their lysosomes 
secreting them the surrounding medium of the mite [19]. The phagocytes may even be lysed releasing 
all their enzymes. It may result in developing a typical inflammatory response which kills the parasite. 
Due to this reaction a granuloma surrounded by inflammatory cell barrier develops around the demo-
dectic nidus. This barrier separates the host organism from the demodectic nidus and prevents pen-
etration of toxic metabolic products of the parasite beyond its borders. That is why our patients were 
administered immunomodulating drugs such as immunofan intramuscularly 1 per day/for 10 days/(inje- 
ctions for immunity) or Cyclopheron intramuscularly 1 per day/for 10 days/(injections for immunity).
Depending on the evolution of a complex of subjective and objective clinical symptoms and 
on the results of the repeated clinical-instrumental examination allowing to assess the nature and 
direction of the changes that there were before the treatment we have adopted the following rating 
scale to assess the degree of efficiency of complex treatment of demodicosis.
The treatment was assessed as effective (recovery) with the normalization of the general con-
dition of the patient, the disappearance of clinical symptoms of the disease, primarily of cutaneous 
manifestations, of objective evidence of the disease, with normalization of hematological and im-
munological tests which indicate the reverse development of changes observed before the treatment.
5. Conclusions
Thus when the treatment of demodicosis is timely and of high quality with taking into 
account individual choice, the correct dosage of a drug, with the selection and adherence to the 
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proper methods the high clinical efficiency can be achieved that is an important lever in the overall 
complex of public health measures against parasitic diseases.
We substantiated and developed the correction principles for disadaptation disorders at liver 
lesions, proposed new ways to enhance adaptive capacities of the organism and effectiveness of 
treatment of demodicosis based on the application of albendazole in the complex treatment with 
hepatoprotectors and immunomodulating therapy.
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